Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Designing personalised cancer treatments.

Journal of controlled release : official journal of the Controlled Release Society - 10 Dec 2013

Cree Ian A

Abstract excerpt

The concept of personalised medicine for cancer is not new. It arguably began with the attempts by Salmon and Hamburger to produce a viable cellular chemosensitivity assay in the 1970s, and continues to this day. While clonogenic assays soon fell out of favour due to their high failure rate, othe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Culture Techniques
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to Neoplasms

Share to Precision Medicine

Share to Prognosis

Share to Real-Time Polymerase Chain Reaction

Source

Identifiers

PMID: 23867286
DOI: 10.1016/j.jconrel.2013.07.007

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23867286-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Designing personalised cancer treatments.PMID 23867286Read ↗

Basic cancer research is essential for the success of personalised medicine.Semantic proximity Read ↗

Personalised cancer medicine.Semantic proximity Read ↗

Choosing anticancer drug targets in the postgenomic era.Semantic proximity Read ↗

Personalizing oncology: perspectives and prospects.Semantic proximity Read ↗

From molecular changes to customised therapy.Semantic proximity Read ↗

Achieving personalized cancer medicine: trials and tribulations.Semantic proximity Read ↗

Redefining cancer: a new paradigm for better and faster treatment innovation.Semantic proximity Read ↗

Personalised medicine for nonsmall cell lung cancer.Semantic proximity Read ↗

The European Union and personalised cancer medicine.Semantic proximity Read ↗

Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints.Semantic proximity Read ↗

Functional precision oncology using patient-derived assays: bridging genotype and phenotype.Semantic proximity Read ↗

Strategies to design clinical studies to identify predictive biomarkers in cancer research.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.